Tocilizumab in severe to critically ill COVID-19 patients: does timing matter?
Abstract Purpose Tocilizumab reduces inflammation during cytokine storms, a key driver of acute respiratory distress syndrome (ARDS) in COVID-19. This study evaluates the impact of tocilizumab timing on outcomes in severe to critically ill COVID-19 patients. Methods This prospective study included p...
Gorde:
| Egile Nagusiak: | , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Springer
2025-09-01
|
| Saila: | Egyptian Journal of Critical Care Medicine |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1007/s44349-025-00026-0 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|